Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA.
The DOI matches its Crossref record.
Abstract
4535 Background: CV9103 is a prostate cancer (PCA) vaccine that contains the four antigens PSA (prostate specific antigen), PSCA, PSMA and STEAP1 as self-adjuvanted full-length mRNAs. Methods: Patients with castrate resistant PCA with rising PSA and predominantly existing metastases (> 80%) were enrolled into a first-in-man phase I/IIa study. The primary endpoint was safety, the secondary immunogenicity. Three different dose levels (256µg, 640µg and 1280µg total mRNA) were tested in the phase I. Patients were vaccinated intradermally in weeks 1, 3, 7, 15 and 23. Blood samples were taken before the first and two weeks after the 2nd to 4th vaccination. Immune responses were assessed by ELISPOT (IFN-g), intracellular cytokine staining (IFN-g, TNFa), tetramer analysis (all ex vivo) or ELISA (PSA). Results: Three patients each were accrued at the low and medium dose level. One dose limiting toxicity, urinary retention, was observed at the high dose level which was expanded to six patients. A maximum tolerated dose was not defined. 389 AEs were reported, and 282 were classified as related. Of these, most were injection-site reactions or flu-like symptoms such as chills and fever. Of 21 serious adverse events, 7 were classified as related. With safety established, the high dose level was expanded by 32 patients (phase IIa). Immunomonitoring was possible in 33 of the 38 patients enrolled at the high dose level. Antigen-specific T-cells were detected in 79% of patients independent of their HLA-background. Importantly, 58% of the immunological responders reacted against multiple antigens. Immune responses were detected against all antigens regardless of cellular localization. The frequency of antigen-unspecific B-cells was increased in 74% patients. In 3 patients, an increase of preexisting anti-PSA antibody levels was measured. NK-cells showed a tendency for increased activation (CD25 and CD69). Individual patients had prolonged stabilization of PSA-levels after initial rises. One patient had a greater than 85% drop in his PSA-level. Conclusions: CV9103 was safe and well-tolerated and displayed an unexpectedly high level of cellular immunogenicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Therapeutic vaccines for cancer: an overview of clinical trials
Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.111 · Cited by 776
Petsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.-J., Stitz, L., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2436 · Cited by 464
Self-citationA novel, disruptive vaccination technology: Self-adjuvanted RNActive ® vaccines
Kallen, K.-J., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T., Thess, A., Baumhof, P., Scheel, B., Koch, S. D., & Fotin-Mleczek, M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25181 · Cited by 223
“Antigen-specific T cells were detected in around 80% of prostate carcinoma patients independent of their HLA-background.(34) Importantly, the majority of immune responders, around 60%, reacted against multiple antigens.”
BackgroundSelf-citationBiomaterials for mRNA delivery
Islam, M. A., Reesor, E. K. G., Xu, Y., Zope, H. R., Zetter, B. R., & Shi, J. (2015) · Biomaterials Science · doi:10.1039/c5bm00198f · Cited by 176
Biomedical applications of mRNA nanomedicine
Xiong, Q., Lee, G. Y., Ding, J., Li, W., & Shi, J. (2018) · Nano Research · doi:10.1007/s12274-018-2146-1 · Cited by 125
Metadata
- Authors
- Kübler, H., Maurer, T., Stenzl, A., Feyerabend, S., Steiner, U., Schostak, M., Schultze-Seemann, W., vom Dorp, F., Pilla, L., Viatali, G., Hampel, C., Wedel, S., Trojan, L., Hiller, K., Sommerauer, M., Jocham, D., Scheel, B., Lander, T., Kallen, K., & Miller, K.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-05-20
- Volume
- 29
- Issue
- 15_suppl
- Pages
- 4535-4535
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2242153643
- Cited by
- 31
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA. https://app.cochat.ai/papers/10.1200/jco.2011.29.15_suppl.4535
- The paper
- Kübler, H., Maurer, T., Stenzl, A., Feyerabend, S., Steiner, U., Schostak, M., Schultze-Seemann, W., vom Dorp, F., Pilla, L., Viatali, G., Hampel, C., Wedel, S., Trojan, L., Hiller, K., Sommerauer, M., Jocham, D., Scheel, B., Lander, T., Kallen, K., & Miller, K. (2011). Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.29.15_suppl.4535
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.